chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She had pain in her arm for 3-4 days and a stiff neck. She kept a heating pad on it. In February, she noticed a spot on her feet near her ankle. She would scratch it and it continued to grow. She went to a dermatologist in May when it was small. She had a biopsy. She was not given anything then. She then called last month on 7/29/2022 as it continued to worsen and could not get an appointment due to being so far out. She has an appointment 9/23/2022. The doctor called her in a prescription for metronidazole, which is not working. She is to take them for about 2 weeks, miss a week and then take again until gone. She has been taking them about a month with no effect. She went to a dermatologist, who gave her some medicine for the itching (loratadine 10mg). She continues to have itching. About once a week, she has burning real bad. She has to pat it to get the sensation away. It has spread all over the bottom of her legs, thighs, her hands and her chest. It is also on her stomach. It seems to move from her stomach to her breast, her arms, hands and middle part of her arms.
One week after my first dose I noticed that my right supraclavicular lymph node became swollen, today is 01/29/2021 and it hasn't gone away. (I got my second dose 2 weeks  after the first one).
Patient states, "I received my flu shot on Wednesday that night I noticed bumps on my left forearm. Thursday they were red and today have a slight burning sensation. It is also on the left side of my face".
Excessive crying.  Unconsolabe.  Swelling of both legs and feet.  Strange gray color.
Injection site turned green; Injection site turned black/Injection site turned blue purple; sore all day; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore all day), VACCINATION SITE BRUISING (Injection site turned black/Injection site turned blue purple) and VACCINATION SITE DISCOLOURATION (Injection site turned green) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025A21A and 038K20A) for COVID-19 vaccination.     Concomitant products included LOVASTATIN, LEVOTHYROXINE and ALENDRONATE SODIUM (FOSAMAX) for an unknown indication.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore all day). On 04-Mar-2021, the patient experienced VACCINATION SITE BRUISING (Injection site turned black/Injection site turned blue purple). On 08-Mar-2021, the patient experienced VACCINATION SITE DISCOLOURATION (Injection site turned green). At the time of the report, PAIN IN EXTREMITY (sore all day), VACCINATION SITE BRUISING (Injection site turned black/Injection site turned blue purple) and VACCINATION SITE DISCOLOURATION (Injection site turned green) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reporter did not allow further contact
Headache, Fever, NauseaVomiting, CHILLS Narrative:
Patient received Menactra and PPD on 7/19/05.  Patient reports itching began evening of 7/19/05, around waist line with progression to rash and hives on neck, stomach and groin the following morning.  No respiratory difficulties reported.  Hives and itching increased in severity during the day.  She saw the nurse practitioner at approximately 3 p.m. and received Decadron 8 mg IM, a Medrol dose pack and Zyrtec p.r.n.  The client's mother reports this morning that the itching and hives are improving but not totally resolved. Patient also received tuberculosis skin test at the same time.
Felt my nose dripping when I got in the car and tissue had blood so I pinched it until I got home. It?s now 6 hours later and still dripping blood.
Vial was initially stored in the refrigerator on 25-Aug-2022 and was administered on 26-Sep-2022; No adverse event; beyond used date was on 24Sep2022 and they used it and made an error/Dose administered after 30-day Use By Date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (beyond used date was on 24Sep2022 and they used it and made an error/Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 25-Aug-2022 and was administered on 26-Sep-2022) and NO ADVERSE EVENT (No adverse event) in a 15-month-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR9236B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Sep-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (beyond used date was on 24Sep2022 and they used it and made an error/Dose administered after 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 25-Aug-2022 and was administered on 26-Sep-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (beyond used date was on 24Sep2022 and they used it and made an error/Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 25-Aug-2022 and was administered on 26-Sep-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (beyond used date was on 24Sep2022 and they used it and made an error/Dose administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 25-Aug-2022 and was administered on 26-Sep-2022).    No concomitant medication was reported.  On 25-Aug-2022, the vial was initially stored in the refrigerator. It was reported that one of the vials beyond used date was on 24-Sep-2022 and they used it and made an error yesterday. Four patients were given doses from that vial.   Vial size was reported as 2.5 mL.  The vial did not underwent any temperature excursions.  No treatment medication was reported.
PT recvd vax & on 14OCT92 pt exp aches, h/a & a fever; No further details were provided;
COVID-19 mRNA/Pfizer-BioNTech vaccine  After 1st dose- arm soreness, nausea, sleepiness and headache for 24 hours After 2nd does- fever 101.0 oral, chills, headache for hours
Pt was admitted due to a subarachnoid hemorrhage following a ground level fall, and was found to be COVID positive.
1.SWELLING IN THE RIGHT ARMPIT, LOW GRADE FEVER. SWELLING IN RIGHT AXILLA(3 CM) NO DEFINED BORDERS,NO HEAT, NO COLOR CHANGES. DELTOID MINOR CHANGES TENDERNESS AT INJECTION SITE, NO LYMHADENOPATHY IN AXILLA OR TROCLEAR AREA 2.BUMPS ON INJECTION SITE
Expired vaccine used; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment medication was reported.  The reporter wanted to know whether patient should get booster again or any testing done.   This case was linked to MOD-2021-392458 (Patient Link).
No adverse event. Concern for only partial dose given by the RN administering because the syringe separated from the needle during administration and it was noted that some of the vaccine was dribbling down the patient's arm. It was unable to be determined how much vaccine was actually administered,  but it was reported that "a couple drops" of the vaccine fell onto the towel. Patient was NOT re-dosed at this point due to inability to determine the amount of vaccine actually administered versus wasted.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. The patient's concurrent conditions and pertinent medical history were not provided. On 18-JUL-2016 the patient was vaccinated with VARIVAX lot # M008171, expiration date: 16-FEB-2018), subcutaneous. There was no concomitant medication reported. The pharmacist reported that on 18-JUL-2016, the patient received an improperly stored dose of VARIVAX. No adverse effect reported. No further information provided. Additional information has been requested.
Tiny red spots appeared on LUE the night of 2/16/19. On 2/17/19, red spots moved down arm to elbow. Feels hot and burning. Bruising appeared in the Left bicep area. Client following up with PCP.
3 cm "wheal" immediately following completion of IM injection. Pt c/o tingling and nausea. Blood pressure elevated to 148/86. Pt placed in supine position. Ice pack applied to injection site. No SOB reported. Pt stabilized and released from clinic.
given 2nd dose of Pfizer only 10 days after receiving second dose. No signs and symptoms of any adverse reaction, patient was observed for 1 hour after vaccine given.
Rash all over light red maculopapular rash. Bump around the site of injection with increase temp and redness/site
Information has been received from a healthcare worker concerning a 61 day old female patient with no pertinent medical history who on 27-MAY-2011 was vaccinated orally with the first dose of ROTATEQ (lot # 668124/0520Z, expiration: 31-MAR-2012) (dose not reported). There was no concomitant medication. The healthcare worker reported that the patient vomited administration of the first dose of ROTATEQ. No treatment was given for the adverse event. No lab diagnostics studies were performed. At the time of reporting, the patient's status was unknown. Additional information has been requested.
Patient received 2nd dose of Pfizer vaccine on 04/22/2021. He had an exposure to Covid-19 around 08/16/2021. Presented to the emergency department on 08/18/2021 with symptoms of Covid. Tested positive for Covid-19 on 08/18/2021. He was admitted to ICU on 08/18/2021 for A Flutter related to Covid-19.
Myalgia, Fever, ErythemaMultiform, BLE pain, gum pain, malaise
Adverse event: Guest was here for first dose of Pfizer COVID vaccine, which was received at 2:29pm. At 2:42 pm LPN observed guest beginning to sweat and stating she was nervous. LPN walked her to the medical tent and called for aid. EMT?s responded approximately 2 minutes later to the medical tent where guest was observed breathing rapidly and repeating that she felt very nervous and felt she might throw up, although she did not. EMT?s took vital signs at 2:50pm as follows: BP 128/76, HR 76, O2 saturation of 99% on room air. Guest was medically cleared by EMT?s around 3pm but remained sitting and resting in the tent until 3:15pm. She remained in the building approx. 10 minutes longer and then left for home. Treatment: Assessment and treatment by EMTs Outcome: Medically cleared, exited facility with friends. Participants: LPN       RN       EMT    EMT
pt recv vax;devel elev ALT 84 IU/DL;MD not sure how many doses of hep B pt had recv;in f/u,MD indicated that there was no causal relationship between vax & pt's exp since pt was vaccinated too long before rise in serum levels;
Information was received from a licensed practical nurse concerning a 6 month old patient of unknown gender. No information was provided regarding the patient's past medical history, concurrent condition, or concomitant medication. On 20-SEP-2016, the patient was vaccinated with an improperly stored dose of ROTATEQ (lot # L046319, expiration date 28-SEP-2017) orally. No symptoms were reported. The administered dose of vaccine experienced a temperature excursion of 32 degrees Fahrenheit for 15 minutes and 31 degrees Fahrenheit for 15 minutes. Data logger was involved. There were no previous excursions and no further temperature excursions reported. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1705USA004952: US-009507513-1705USA004965: US-009507513-1608USA012794: US-009507513-1608USA012908: US-009507513-1608USA012916: US-009507513-1705USA004976: US-009507513-1705USA004977: US-009507513-1705USA004978: US-009507513-1705USA004979: US-009507513-1705USA004980: US-009507513-1705USA004981: US-009507513-1705USA004982: US-009507513-1705USA004983: US-009507513-1705USA004984: US-009507513-1705USA004985: US-009507513-1705USA004942: US-009507513-1705USA004944: US-009507513-1705USA004945: US-009507513-1705USA004947: US-009507513-1705USA004948: US-009507513-1705USA004949: US-009507513-1705USA004950: US-009507513-1705USA004951: US-009507513-1705USA004953: US-009507513-1705USA004955: US-009507513-1705USA004956: US-009507513-1705USA004957: US-009507513-1705USA004958: US-009507513-1705USA004959: US-009507513-1705USA004960: US-009507513-1705USA004961: US-009507513-1705USA004962: US-009507513-1705USA004963: US-009507513-1705USA004964: US-009507513-1705USA004966: US-009507513-1705USA004968: US-009507513-1705USA004969: US-009507513-1705USA004970: US-009507513-1705USA004971: US-009507513-1705USA004972: US-009507513-1705USA004973: US-009507513-1705USA004974: US-009507513-1705USA004975: US-009507513-1705USA004946: US-009507513-1705USA005004: US-009507513-1705USA005005: US-009507513-1705USA005006: US-009507513-1705USA005007: US-009507513-1705USA004894: US-009507513-1705USA004895: US-009507513-1705USA004896: US-009507513-1705USA004897: US-009507513-1705USA004898: US-009507513-1705USA004899: US-009507513-1705USA004893: US-009507513-1705USA004892: US-009507513-1705USA004890: US-009507513-1705USA004889: US-009507513-1705USA004888: US-009507513-1705USA004887: US-009507513-1705USA004891:
3 1/2 in induration with redness and warmth. Painful to touch.
I felt some soreness as expected in my left upper arm. That did not alarm me at all but I was shocked to see the following day that I had vaginal bleeding. I am not scheduled to have my period to the 20th of Jan so this would be very early. I have now urinated a second time and am still spotting when I pee.
Severe vertigo which caused vomiting; Severe vertigo which caused vomiting; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 28Mar2021 at 13:30 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriatic arthritis, obese (obesity) and high BP (blood pressure high). The patient had allergy to some unspecified antibiotics. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation and experienced no side effects. On an unknown date in Mar2021 (reported as 04Apr2021), the patient experienced nausea. It was reported that day 1 was fine. On 29Mar2021 (reported as 04Apr2021), day 2 after the vaccine the patient experienced severe vertigo which caused vomiting. On 01Apr2021, day 5, the symptoms are diminishing but still present. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event nausea was recovered on an unknown date in Mar2021 (reported as after day 2, the patient did not have nausea). The clinical outcomes of the events severe vertigo which caused vomiting were recovering at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Lymph node swelling under the right Arm on day 2 of the 2nd Vaccine; Swelling is still there on day 3; Extreme indegestion; This is a spontaneous report from a contactable consumer (patient). A 48-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on 08Mar2021 at 13:15 (at the age of 48-years) as dose 2, single in the right arm for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on 15Feb2021 at 13:15 (at the age of 48-years) as dose 1, single in the left arm for covid-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications in two weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 09Mar2021 at 16:00, the patient experienced lymph node swelling under the right arm on day 2 of the 2nd Vaccine, swelling is still there on day 3, extreme indigestion the day after both shots. Patient did not received treatment for events. The outcome of the events was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
severe headache; This spontaneous case was reported by a physician and describes the occurrence of HEADACHE (severe headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On an unknown date, the patient experienced HEADACHE (severe headache). At the time of the report, HEADACHE (severe headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant Medications were  provided by Reporter. No Treatment Medications were  provided by Reporter.   Reporter did not allow further contact
Patient states his injection site swelled to the size of a tennis ball, was sore to the touch, felt a little out of sorts for 1 day, swelling lasted 5-6 days.
Rash developed on underside of both forearms and biceps first about six days after 2nd shot.  Other parts of the body developed rash gradually.  Other rash areas include back of legs, midsection/buttocks, and eye lids.  Non-emergency.  Just red, irritation, and itchy.  Its been over two days since it started.  I've just taken Benadryl which seems to help.
To ER via ambulance 104 temp at ER on arrival. Mom went to check on pt after crying out, eyes rolled back, heart beating fast, mom took child downstairs to family. Dx at ER sz type activity, no hx of sz, mom doesn't describe any shaking type behavior.
tenderness; swelling on both arm pit (left arm, right arm auxillary swelling) and very painful; swelling on both arm pit (left arm, right arm auxillary swelling) and very painful; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (tenderness), LYMPHADENOPATHY (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful) and AXILLARY PAIN (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, the patient experienced TENDERNESS (tenderness), LYMPHADENOPATHY (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful) and AXILLARY PAIN (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, TENDERNESS (tenderness) and AXILLARY PAIN (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful) outcome was unknown and LYMPHADENOPATHY (swelling on both arm pit (left arm, right arm auxillary swelling) and very painful) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medication was reported.    This case was linked to MOD-2021-117053.   Most recent FOLLOW-UP information incorporated above includes: On 10-May-2021: Follow up information was received and event outcome was updated.
pt recv vax & a red blotchy rash appeared on both arms spreading to torso neck, face & legs; no LOC or resp difficulty
Patient reports lightheadedness, burning and lump in throat.  Benadryl given.   symptoms improved by 2:51pm.
Arm Pain, Cough, Fever (3 times during night, each broke) Upset stomach, headache, tiredness.
Narrative: COVID infection following COVID vaccine series 05/22, Morderna  , dose #1 (private sector- Publix) 06/19, Moderna  , dose #2 (private sector- Publix) 12/25 COVID swab, result: detected 12/25 pt cc: exposure: unknown 12/25 pt admit to ED cc: cough with chest pain dx: covid 19 infection LOS:  1 day 12/25 SARS-COV-2 Variant Sequencing: pending 12/25 CXR impression: No acute cardiopulmonary abnormality.
Transverse myelitis T3-T11 with paralysis, ongoing.  8/07/2007 This report upgraded from Non-serious.  Nothing checked in Box 8, but pt is hospitalized.   09/04/2007 Lengthy MR received from hospital for DOS 7/24/2007-8/9/2007. Pt was received via air flight from hospital in Hong Kong where he presented to the ER upon arrival in that country on 6/8/2007 with fever, back pain, difficulty walking, and urinary difficulties. Paraplegia did not respond to steroids or plasmapheresis.  On 7/12/2007 pt experienced LOC and twitching of upper limbs.  Possible infarct. Motor residual effect difficult to detect given transverse myelitis. Stable to transfer back to USA on 7/24/2007. Physiatry and neuro consults 7/25/07.  PE (+) for ankle edema, flaccid lower extremities, orthostatic hypotension, Lower extremity strength 0/5.  Spotty sensation in the feet. Impression:-Internal medicine: Transverse Myelitis.  Cerebrovascular Disease.  Hyperlipidemia.   Impression- Physiatry: Decreased ADLs and mobility and Transverse Myelitis with sensory level about T6.  Transverse Myelitis with T8-9 uptake.  Neurogenic Bowel and Bladder.  Left cerebellar, right frontoparietal infarcts after some jerking and LOC. Impression-Neurology:  Possible Acute Idiopathic Transverse Myelitis.  Event 7/13/07 was positional syncope from orthostatic hypotension due to spinal cord injury-followed by a brief syncopal convulsion. Newly discovered lesions possibly ADEM. 09/24/2007 D/C Summary for D/C date 8/30/2007 recieved with the following DX:  T8-9 Transverse Myelitis.  Neurogenic Bowel and Bladder.  Neuropathic Pain at T8-9 level of the Lesion. Orthostasis.  Prostatitis.  Gilbert's Syndrome.  Cerebrovascular Disease. Upon D/C pt's strenght in LEs still 0/5.  Sensation decreased below T6.  Using wheelchair for mobility and requiring assistance with ADLs.